AAA
NTLA icon

Affinity Asset Advisors’s Intellia Therapeutics NTLA Stock Holding History

Affinity Asset Advisors’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-10,000
Closed -$1.18M – 69
2021
Q4 		$1.18M Sell
10,000
-5,000
-33% -$626K 0.43% 44
2021
Q3 		$2.01M Buy
15,000
+5,000
+50% +$757K 0.51% 40
2021
Q2 		$1.62M Buy
+10,000
New +$779K 0.58% 40

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Affinity Asset Advisors's NTLA Position: Q1 2022 in Review

Affinity Asset Advisors sold out of Intellia Therapeutics (NTLA) in Q1 2022, closing a stake of 10,000 shares — an estimated $1.18M sold.

Affinity Asset Advisors first reported a position in NTLA in Q2 2021 and held it in 3 quarters. The position peaked at $2.01M in Q3 2021. 348 funds tracked by Wall St. Rank hold NTLA as of Q1 2022.

  • Affinity Asset Advisors reported no remaining Intellia Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Affinity Asset Advisors sold 10,000 Intellia Therapeutics shares in Q1 2022, an estimated $1.18M.
  • Affinity Asset Advisors first reported a position in Intellia Therapeutics in Q2 2021 and held it in 3 quarters.
  • Affinity Asset Advisors's Intellia Therapeutics position peaked at $2.01M in Q3 2021.
  • 348 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2022.

Based on Affinity Asset Advisors's 13F filing for Q1 2022, filed 13 May 2022.